Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levosimendan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B known ✓ | Q13370 | 16/20 | 1.00 |
| ▸ | PDE3A known ✓ | Q14432 | 16/20 | 1.00 |
| ▸ | TNNC1 known ✓ | P63316 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 2/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levosimendan SCHEMBL1818300 | 1.00 | PDE3B (1.00) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| Simendan SCHEMBL80460 | 1.00 | PDE3B (1.00) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| Levosimendan SCHEMBL7417215 | 1.00 | PDE3B (1.00) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| Levosimendan SCHEMBL30307096 | 0.99 | PDE3B (0.98) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| Levosimendan SCHEMBL27742947 | 0.99 | PDE3B (0.98) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| Levosimendan SCHEMBL4737565 | 0.96 | PDE3B (0.91) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| Simendan SCHEMBL23630217 | 0.94 | PDE3B (0.88) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| Levosimendan SCHEMBL29197894 | 0.90 | PDE3B (0.81) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| SCHEMBL11946689 | 0.89 | PDE3B (0.80) | PDE3BPDE3ATNNC1KDM4EALDH1A1 | |
| SCHEMBL8320982 | 0.87 | PDE3B (0.77) | PDE3BPDE3ATNNC1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4072 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629334-B2 | Lipid emulsions and uses thereof | RESQ PHARMA, INC. (US) | 2026-05-19 | — | — | US | claimed |
| US-12616694-B2 | Pharmaceutical compositions for subcutaneous administration of levosimendan | TENAX THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | claimed |
| EP-3934654-B1 | ISTAROXIME OR ITS METABOLITE PST-3093 FOR USE AS INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | WINDTREE THERAPEUTICS INC (US) | 2026-04-29 | — | — | EP | claimed |
| US-12605366-B2 | Telmisartan for the treatment of hypertension in dogs | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2026-04-21 | — | — | US | claimed |
| EP-4702057-A1 | IN VIVO IMAGING OF AN ALS BIOMARKER AND MEANS THEREFOR | AL-S Pharma AG (CH) | 2026-03-04 | — | — | EP | claimed |
| EP-4076398-B1 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-PEF) | TENAX THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | claimed |
| US-20260021036-A1 | FLEXIBLE BIODEGRADABLE MICRONEEDLES | SHEBA IMPACT LTD (IL) | 2026-01-22 | — | — | US | claimed |
| EP-4081242-B1 | TREATMENT OF ACUTE HEART FAILURE | AnaCardio R&D AB (SE) | 2025-09-10 | — | — | EP | claimed |
| US-20250231197-A1 | BIOMARKER IDENTIFICATION FOR IMMINENT AND/OR IMPENDING HEART FAILURE | Endothelium Scanning Nanotechnology Limited (AU) | 2025-07-17 | — | — | US | claimed |
| US-12343350-B2 | Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF) | WINDTREE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | claimed |
| EP-1052973-A1 | TRANSMUCOSAL FORMULATIONS OF LEVOSIMENDAN | ORION CORPORATION (FI) | 2000-11-22 | — | — | EP | claimed |
| CN-1271282-A | Oral compositions of levosimendan | ORION CORP (FI) | 2000-10-25 | — | — | CN | claimed |
| EP-1014987-A1 | ORAL COMPOSITIONS OF LEVOSIMENDAN | ORION CORPORATION (FI) | 2000-07-05 | — | — | EP | claimed |
| WO-1999065888-A2 | A REFERENCE COMPOUND FOR USE IN THE ANALYSIS OF LEVOSIMENDAN BATCHES | ORION CORPORATION (FI) | 1999-12-23 | — | — | WO | claimed |
| WO-1999056134-A1 | A METHOD FOR MONITORING THE TOLERABILITY OF LEVOSIMENDAN ADMINISTRATION | ORION CORPORATION (FI) | 1999-11-04 | — | — | WO | claimed |
| WO-1999055337-A1 | STABILE COMPOSITIONS COMPRISING LEVOSIMENDAN AND ALGINIC ACID | ORION CORPORATION (FI) | 1999-11-04 | — | — | WO | claimed |
| WO-1999055305-A2 | CONTROLLED RELEASE PERORAL COMPOSITIONS OF LEVOSIMENDAN | ORION CORPORATION (FI) | 1999-11-04 | — | — | WO | claimed |
| WO-1999032081-A1 | TRANSMUCOSAL FORMULATIONS OF LEVOSIMENDAN | ORION CORPORATION (FI) | 1999-07-01 | — | — | WO | claimed |
| WO-1999016443-A1 | ORAL COMPOSITIONS OF LEVOSIMENDAN | ORION CORPORATION (FI) | 1999-04-08 | — | — | WO | claimed |
| WO-1998031380-A1 | PHALLOIDIN DERIVATIVES AND ANALOGS TO TREAT CONGESTIVE HEART FAILURE | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1998-07-23 | — | — | WO | claimed |